Albumin in Cirrhosis: More Than a Colloid
Purpose of review
Albumin has repeatedly been shown to be beneficial in treating patients with decompensated cirrhosis. We reviewed the medical literature regarding indications for the use of intravenous albumin in cirrhosis, with particular focus on the ways in which albumin can help mitigate hepatorenal physiology.
Albumin has long been used as the preferred agent for volume expansion in patients with decompensated cirrhosis. It is used in conjunction with vasoconstrictors for the treatment of type 1 hepatorenal syndrome, and in combination with antibiotics for the treatment of spontaneous bacterial peritonitis. When given at the time of large volume paracentesis, albumin is known to help reduce the incidence of post-paracentesis circulatory dysfunction. Recently, albumin has been shown to improve outcomes in hospitalized patients with cirrhosis and hyponatremia, and has also shown promise in reducing mortality and hospitalizations in outpatients with both diuretic resistant and uncomplicated ascites. It is increasingly clear that these benefits derive from a combination of the oncotic and non-oncotic properties of albumin, and from the effects of albumin administration on effective arterial blood volume.
Albumin is an effective treatment for multiple complications encountered in patients with decompensated cirrhosis.
KeywordsCirrhosis Albumin Hepatorenal syndrome Ascites Hyponatremia
Compliance with Ethical Standards
Conflict of Interest
Cary H. Paine declares that he has no conflict of interest. Scott W. Biggins declares that he has no conflict of interest. Raimund H. Pichler declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 1.Chapter XII: The bovine and human albumin programs. In: US Army Medical Department, Office of Medical History. 2018 https://history.amedd.army.mil/booksdocs/wwii/blood/chapter12.htm. Accessed 24 Dec 2018.
- 2.Skillman JJ, Restall DS, Salzman EW. Randomized trial of albumin vs. electrolyte solutions during abdominal aortic operations. Surgery. 1975;78:291–303.Google Scholar
- 8.•• Di Pascoli M, Fasolato S, Piano S, Bolognesi M, Angeli P. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. Liver Int. 2019;39:98–105. Recent randomized controlled trial showing a mortality benefit from outpatient albumin administration in diuretic-resistant ascites. CrossRefGoogle Scholar
- 9.•• Bajaj, JS TP, O’Leary JG, et al. The impact of albumin use on resolution of hyponatremia in hospitalized patients with cirrhosis. Am J Gastroenterol. 2018;113:1339–44 Recent retrospective study showing an association between albumin administration and improved outcomes in cirrhotic patients with hyponatremia. CrossRefGoogle Scholar
- 10.•• Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet. 2018;391:2417–29 The first randomized controlled trial showing a benefit from albumin administration in uncomplicated ascites. CrossRefGoogle Scholar
- 12.Safety of Albumin Administration in Critically Ill Patients. 2018 https://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/BloodSafety/ucm095539.htm. Accessed 24 Dec 2018.
- 15.Peters T. All about albumin. San Diego, CA: Academic Press; 1996.Google Scholar
- 44.Ginès P, Titó L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology. 1988;94:1493–502.Google Scholar